HC Wainwright Boosts TG Therapeutics (NASDAQ:TGTX) Price Tar

TG Therapeutics (NASDAQ:TGTX – Free Report) had its price objective increased by HC Wainwright from $45.00 to $49.00 in a research report report published on Thursday morning, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other analysts have also recently issued reports on the stock. The Goldman Sachs […]

Related Keywords

Los Angeles , California , United States , Laurencen Charney , , Tg Therapeutics Company Profile , Goldman Sachs Group , Principal Financial Group Inc , Wealth Effects , Los Angeles Capital Management , Hennion Walsh Asset Management Inc , Jpmorgan Chase Co , Raymond James Financial Services Advisors Inc , Tg Therapeutics Inc , Free Report , Moderate Buy , Trading Down , Get Free Report , Director Laurence , Financial Group , James Financial Services Advisors , Walsh Asset Management , Angeles Capital Management , Tg Therapeutics , Nasdaq Tgtx , Tgtx , Medical , Boost Price Target , Hc Wainwright ,